Draft:Rattan Ramandeep

Early Life
Ramandeep was born in Chandigarh India, in the Northern part of Pnjab to parents Daljit Singh Rattan and Jaswinder Jolly. One of 5 siblings, Ramandeep is the one of the only members of her family to immigrate to the United States to pursue her research career with the rest of her family in India and one sister in Canada. Rattan came to the United States on December 24th, 1999 with her husband Shailendra Giri Prijab to complete her Ph.D. in microbiology and eventually find work in the Henry Ford Hospital Research Center.

After completing her Bachelors in Clinical Lab science and receiving hands on experience in hospital based settings Rattan worked as a pharmaceutical technician building diagnostic kits before she found her interest in microbiology while completing her masters at Central Research Institute. From there, under her research with her Ph.D. Mentor was Dr. Inderjit Singh Rattan studied the effects of Metformin on AMPK activator and was introduced into the field of ovarian cancer research and has since undergone numerous research initiatives in understanding the process of tumor proliferation and in recent years specifically how metabolic and caloric restrictions affect the tumor growth process.

Education

 * Bachelors in medical Laboratory Technology, PGIMER, India, Chandigarh, India, July 1996
 * Masters in Microbiology Central Research Institute HP, India, August 1998
 * Ph.D. in Molecular and Cell Biology Medical Institute of South Carolina Charleston, SC, December 2005, doctoral thesis on targeting glioma statins

Post Graduate Training

 * Graduate Student, Dept. of Pediatrics, Medical University of South Carolina, Charleston, SC 2000-2005
 * Post-Doctoral Fellow, Dept. of Laboratory Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic, Rochester, MN 2006-2010
 * Research Associate, Dept Laboratory Medicine and Pathology, Division Of Experimental Pathology, Mayo College of Medicinee, Rochester MN 2010-2011

Honors and Awards

 * DOD-CDMRP-OCRP Investigator Initiated Award 2024-2028
 * DOD-CDMRP-OCRP Investigator Initiated Award (returned) 2020-2024
 * Henry Ford Hospital 2018 Best Publication of the Year 2018
 * DOD-CDMRP-OCRP Investigator Initiated Award 2017-2020
 * Hartman Funding Near Miss Initiative, Henry Ford Cancer Institute 2017-2018
 * Belinda Sue Make a Difference Award 2016
 * Michigan Cancer Ovarian Alliance Award 2015-2016
 * Henry Ford Cancer Institute Pilot Research Award 2015-2016
 * DOD-CDMRP-OCRP Pilot Award 2011-2013
 * DOD-CDMRP-OCRP Transitional Pilot Award 2011-2013
 * Minnesota Ovarian Cancer Alliance Award 2010-2011
 * Marsha Rivkin Scholar Award for Ovarian Cancer Research 2010-2011 for research on the novel oncogene TCEAL7, and information regarding the affects of TCEAL7 on regulation of other oncogenes.
 * Ovarian Cancer Research Foundation Program of Excellence Award 2006-2008
 * Scholar in Training Award, AARC International Conference 2007
 * Junior Research Fellowship in Dept. of Biochemistry, PGIMER, India 1998-1999

Research
Rattan has been cited 4,806 times according to her google scholar page and has 57 citations in her name. Most of her research over her career has been focus on Ovarian Cancer. Her most popular research citation being


 * 1) 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside Inhibits Cancer Cell Proliferation in Vitro and in Vivo via AMP-activated Protein Kinase  in which they found that the activation of AMP Kinase inhibits the cell cycle and induces cell apoptosis helping prevent the proliferation of the tumor.  While there is an increase in the p53 gene in this experiment there was enough cell death and apoptosis from the heightened stress levels producing more and more AMPK leading to inhibition of cellular production.
 * 2) Metformin Suppresses Ovarian Cancer Growth and Metastasis with Enhancement of Cisplatin Cytotoxicity In Vivo In this research as a part of her post doctoral experience Rattan and her colleagues were working on establishing the mechanisms of metformin, a drug that at this time was commonly being used for diabetes, and explored the relationship between Metformin activating AMP Kinase. They found that the Metformin, when paired with another chemotherapy drug cisplatin, decreased the tumor cell growth by process of inhibiting cell proliferation.  Because of this research there was also further correlation between the mitochondria of the cell and there mechanisms reacting to the AMP Kinase which yielded further research into those mechanisms.
 * 3) Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer In this research Rattan was apart of the team working on understanding the differences in the presence of Effector T-cells and their contribution to chemo resistance with interactions from the fibroblasts. It was found that the fibroblasts increase the chemoresistance in certain cases by attacking the cisplatin.
 * 4) Abstract 851: Uncovering a novel role of succinate metabolism in tregulatory cells of aged epithelial ovarian cancer mice In an current abstract Rattan and her team are working to understand how the metabolism affects the rate of cancer growth in mice. In this abstract the researchers study the difference between age related metabolic dysfunction and cells within the immune system, working to see if there is a difference in survival rates and tumor growth rates.

In further research Ramandeep and her team are planning on continuing to explore the caloric restriction and metabolism affects on proliferation of tumor cells as well as the differences between BRCA 1 and BRCA 2.